NEW YORK, NY / ACCESSWIRE / February 6, 2017 / Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announced today that it will be presenting at the 2nd annual Disruptive Growth & Healthcare Conference on Wednesday, February 15, 2017 at 11:15 AM EST. Delcath President & Chief Executive Officer, Dr. Jennifer K. Simpson, will be presenting, as well as meeting with investors.
The 2017 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.
A webcast of Dr. Simpson's presentation will be available at http://www.investorcalendar.com/event/11176.
News Compliments of Accesswire.
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product - Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) - is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and a global Phase 2 clinical trial in Europe and the U.S. to investigate the Melphalan/HDS system for the treatment of primary liver cancer (HCC) and intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.
For those interested in attending, please visit www.DisruptNYC.com for more information.
Contact:
Tristan Traywick
Managing Director
CORE IR
377 Oak Street
Garden City, NY 11530
Tel: 206-946-1903
Email: tt@coreir.com
www.coreir.com
SOURCE: Delcath Systems, Inc.
ReleaseID: 454354
